Dailypharm Live Search Close

Reimbursement imminent for some anticancer drugs in KOR

By Lee, Tak-Sun | translator Kim, Jung-Ju

23.09.19 12:10:53

°¡³ª´Ù¶ó 0
NHIS pricing negotiations ongoing for Jemperli and Braftovi



Jeperli Inj (dostarlimab, GSK) and Braftovi Cap 75mg (encorafenib, Ono), which passed the Drug Reimbursement Evaluation Committee meeting last month, are currently in drug price negotiations with the National Health Insurance Service.

According to industry sources on the 19th, the National Health Insurance Service recently updated the list of drugs receiving new drug pricing negotiations.

According to the update, the drugs currently subject to negotiation are the asthma antibody treatment Cinqair Inj (Teva), Braftovi Cap 75mg, and Jeperli Inj.

On the other hand, ¡®Evrysdi Dry Syrup (risdiplam, Roche)', a spinal muscular atrophy (SMA) treatment that had been under negotiat

Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)